trending Market Intelligence /marketintelligence/en/news-insights/trending/3w1yN4vtPqnbW2qYhF1S_A2 content esgSubNav
In This List

Australis Capital to acquire Folium Biosciences in all-stock deal

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Australis Capital to acquire Folium Biosciences in all-stock deal

Australis Capital Inc. agreed to acquire Folium Biosciences LLC, a private manufacturer and distributor of cannabinoids, in an all-stock deal.

On completion, current members of Folium will own 89% of Australis Capital. Australis Capital, a venture capital firm that invests in cannabis and real estate, will rebrand as Folium Biosciences before the transaction.

Las Vegas-based Australis Capital plans to seek shareholder approval for the proposed transaction in the future.